Brain-derived blood extracellular vesicles as potential biomarkers in multiple sclerosis (MS): Pilot results from relapsing MS patients receiving anti-CD20 therapy

被引：0
|
作者：
Anandan, Shamundeeswari [1 ,2 ]
Feliciello, Giancarlo [3 ]
Werner-Klein, Melanie [4 ]
Stojanovic, Natasa [3 ]
Torkildsen, Oivind [1 ,2 ]
Myhr, Kjell-Morten [1 ,2 ]
机构：
[1] Haukeland Hosp, Dept Neurol, NeuroSysMed, Bergen, Norway
[2] Univ Bergen, Dept Clin Med, Bergen, Norway
[3] Fraunhofer Inst Toxicol & Expt Med, Personalized Tumor Therapy, Regensburg, Germany
[4] Univ Regensburg, Expt Med & Therapy Res, Regensburg, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P257/188
引用
收藏
页码：305 / 306
页数：2
相关论文
共 30 条
  • [1] Safety and efficacy of cladribine therapy following a treatment with anti-CD20 compounds in relapsing multiple sclerosis patients: a pilot study
    Sacco, R.
    Disanto, G.
    Pravata, E.
    Gobbi, C.
    Zecca, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 852 - 852
  • [2] Enhanced Isolation Technique for Brain-Derived Extracellular Vesicles provides a new source of blood-derived biomarkers in Multiple Sclerosis
    Perriot, Sylvain
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 984 - 984
  • [3] Anti-CD20 monoclonal antibody in multiple sclerosis therapy: the results of phase 3 clinical studies on relapsing and primary progressive multiple sclerosis
    Maciejowski, Maciej
    AKTUALNOSCI NEUROLOGICZNE, 2015, 15 (03): : 150 - 154
  • [4] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
    Vollmer, Brandi
    Nair, Kavita
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2019, 92 (15)
  • [5] OLIKOS Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients who Transition from Intravenous Anti-CD20 Therapy
    Hua, Le H.
    Alvarez, Enrique
    Foley, John
    Henry, Roland G.
    Brown, Joel
    Camacho, Elizabeth
    Meng, Xiangyi
    Ziehn, Marina
    Brown, Brandon
    Greenberg, Benjamin M.
    NEUROLOGY, 2021, 96 (15)
  • [6] Olikos study design: exploring maintained ofatumumab efficacy in relapsing ms patients who transition from intravenous anti-cd20 therapy
    Greenberg, B.
    Alvarez, E.
    Foley, J.
    Henry, R.
    Brown, J.
    Camacho, E.
    Meng, X.
    Ziehn, M.
    Brown, B.
    Hua, L. H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 226 - 226
  • [7] Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy
    Koc, Emine Rabia
    Turan, Omer Faruk
    Saridas, Furkan
    Menguc, Bedirhan
    Minaz, Sema Nur
    Ozkaya, Guven
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2023, 26 (05) : 697 - 701
  • [8] Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Houtsma, Erik
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1167 - 1168
  • [9] Small extracellular vesicles derived from b naive and memory lymphocytes in multiple sclerosis relapse and remission patients as potential plasma biomarkers
    Pineiro-Abuin, A.
    Sanchez-Franco, C.
    Alvarez-Rodriguez, E.
    Bello-Otero, L.
    Lopez-Caneda, C.
    Aguado-Valcarcel, M.
    Gonzalez-Fernandez, A.
    Peleteiro, M.
    Gonzalez-Suarez, I.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 310 - 310
  • [10] Relative frequency of CD11c+peripheral blood B cells increases after anti-CD20 monoclonal antibody therapy in relapsing-remitting multiple sclerosis
    El Mahdaoui, Sahla
    Hansen, Marie Mathilde
    von Essen, Marina Rode
    Hvalkof, Victoria
    Sellebjerg, Finn
    Christensen, Jeppe Romme
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 235 - 236
123